e.l.f. Beauty (ELF) files Form 144 to sell 565 restricted shares
Rhea-AI Filing Summary
Form 144 notice for e.l.f. Beauty, Inc. (ELF): The filer proposes to sell 565 shares of common stock through Morgan Stanley Smith Barney (New York) on 08/28/2025 with an aggregate market value of $73,563.00. The issuer reports 56,734,903 shares outstanding. The securities were acquired as restricted stock on 08/22/2025 from the issuer and payment is recorded on 08/22/2025. The filer reports “Nothing to Report” for sales during the past three months and certifies no undisclosed material adverse information is known.
Positive
- Complete transaction details provided: acquisition date, payment date, broker, and proposed sale date are all disclosed
- No sales in prior three months reported, simplifying aggregation and compliance review
Negative
- Proposed sale of 565 shares valued at $73,563.00 reduces insider-held restricted shares
- Filer did not identify the specific person by name in the provided extract (only account relationship language appears)
Insights
TL;DR: Routine Form 144 filing disclosing a proposed sale of a small block of restricted shares with full acquisition details provided.
The filing lists a proposed sale of 565 common shares valued at $73,563 through Morgan Stanley Smith Barney on 08/28/2025. The shares were acquired as restricted stock on 08/22/2025 and paid for the same day. No other sales in the prior three months are reported. For investors, this is a transparent disclosure of an intended sale by a person associated with the issuer; the filing contains acquisition dates, payment information, broker details, and outstanding shares, all useful for recordkeeping and compliance review.
TL;DR: Compliance-focused disclosure that meets Rule 144 reporting elements without indicating material corporate changes.
The notice includes the required Rule 144 elements: class of security, broker identity, number of shares, aggregate value, outstanding share count, acquisition method (restricted stock), acquisition and payment dates, and the proposed sale date. The signer affirms no undisclosed material adverse information. This filing appears procedural and aimed at regulatory compliance rather than communicating a material event affecting corporate governance or strategy.